PRESS RELEASE SUMMIT, N meds online .J.— – Celgene Corporation today announced the election of Michael W. Bonney to its Panel of Directors. Mr. Bonney served as CEO and a known member of the Plank of Directors of Cubist Pharmaceuticals, Inc. From 2003 until his pension on December 31 June, 2014. In addition to his tenure as CEO of Cubist, Mr. Bonney's vast healthcare encounter includes serving seeing that President and Chief Operating Officer of Cubist from January 2002 to June 2003; holding various positions of raising responsibility at Biogen, Inc., from 1995 – 2001; and serving in positions of increasing responsibility in product sales, marketing and strategic preparation at Zeneca Pharmaceuticals over an eleven calendar year period.
He received his B.A. In economics from Amherst College, Phi Beta Kappa. AboutCelgene Celgene Company, headquartered inSummit, NJ, is an integrated global pharmaceutical firm engaged mainly in the discovery, development and commercialization of innovative therapies for the treating inflammatory and cancer diseases through gene and proteins regulation. To find out more, please visit FollowCelgeneon Twitter @Celgene, and onPinterestandLinkedIn.. PRESS RELEASE SUMMIT, N.J.— – Celgene Corporation today announced the appointment of Gerald F. Masoudi simply because Executive Vice President, General Counsel and Corporate Secretary, june 1 effective, 2015. Mr. Masoudi will be responsible for global legal technique and can serve on the organization's Executive Committee. Mr. Masoudi will succeed Lawrence V. Stein, Celgene's Executive Vice President, General Counsel and Corporate Secretary since 2012, who is retiring from Celgene carrying out a distinguished business and legal career that also included serving while General Counsel for Wyeth and Genetics Institute and while a partner at regulations company Arnold & Porter.